FR1525186A
(fr)
|
1967-03-29 |
1968-05-17 |
Roussel Uclaf |
Nouvelles pénicillines et procédé de préparation
|
EP0028489B1
(en)
|
1979-11-05 |
1983-10-05 |
Beecham Group Plc |
Enzyme derivatives, and their preparation
|
DE4034829A1
(de)
|
1990-11-02 |
1992-05-07 |
Merck Patent Gmbh |
Cyclopeptide
|
JP3190431B2
(ja)
|
1991-07-01 |
2001-07-23 |
三菱化学株式会社 |
ケトン誘導体
|
GB9206757D0
(en)
|
1992-03-27 |
1992-05-13 |
Ferring Bv |
Novel peptide receptor ligands
|
US5624936A
(en)
|
1995-03-29 |
1997-04-29 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
WO1996034010A2
(en)
|
1995-03-29 |
1996-10-31 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
EP0891352A4
(en)
|
1996-04-03 |
2001-08-16 |
Merck & Co Inc |
INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
|
US5869682A
(en)
|
1996-04-03 |
1999-02-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
PE121699A1
(es)
|
1997-02-18 |
1999-12-08 |
Boehringer Ingelheim Pharma |
Heterociclos biciclicos disustituidos como inhibidores de la trombina
|
ZA985247B
(en)
|
1997-06-19 |
1999-12-17 |
Du Pont Merck Pharma |
Guanidine mimics as factor Xa inhibitors.
|
TW557297B
(en)
|
1997-09-26 |
2003-10-11 |
Abbott Lab |
Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
|
DE69939689D1
(de)
|
1998-03-19 |
2008-11-20 |
Vertex Pharma |
Caspase inhibitoren
|
CN1138778C
(zh)
|
1998-05-26 |
2004-02-18 |
沃尼尔·朗伯公司 |
用作细胞增殖抑制剂的二环嘧啶及二环3,4-二氢嘧啶化合物及用途
|
US6307049B1
(en)
|
1998-09-30 |
2001-10-23 |
The Procter & Gamble Co. |
Heterocyclic 2-substituted ketoamides
|
EP1016663A1
(en)
|
1999-01-02 |
2000-07-05 |
Aventis Pharma Deutschland GmbH |
Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
|
CZ20012379A3
(cs)
|
1999-01-02 |
2001-09-12 |
Aventis Pharma Deutschland Gmbh |
Nové deriváty malonové kyseliny, způsoby jejich přípravy, použití a farmaceutické přípravky obsahující tyto deriváty (inhibitory aktivity faktoru Xa)
|
CA2369378A1
(en)
|
1999-04-09 |
2000-10-19 |
Basf Aktiengesellschaft |
Low-molecular inhibitors of complement proteases
|
EP1192135A2
(en)
|
1999-06-14 |
2002-04-03 |
Eli Lilly And Company |
Serine protease inhibitors
|
DE19962924A1
(de)
|
1999-12-24 |
2001-07-05 |
Bayer Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
EP1125925A1
(en)
|
2000-02-15 |
2001-08-22 |
Applied Research Systems ARS Holding N.V. |
Amine derivatives for the treatment of apoptosis
|
DE60115227T2
(de)
|
2000-05-11 |
2006-08-24 |
Bristol-Myers Squibb Co. |
Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
AR035216A1
(es)
|
2000-12-01 |
2004-05-05 |
Astrazeneca Ab |
Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
|
WO2003011222A2
(en)
|
2001-07-27 |
2003-02-13 |
Merck & Co., Inc. |
Thrombin inhibitors
|
US6951840B2
(en)
|
2001-08-31 |
2005-10-04 |
Eli Lilly And Company |
Lipoglycopeptide antibiotics
|
KR100909141B1
(ko)
|
2001-09-21 |
2009-07-23 |
브리스톨-마이어스스퀴브컴파니 |
인자 Xa 억제제로서의 락탐-함유 화합물 및 그의 유도체
|
US6649606B1
(en)
|
2001-11-09 |
2003-11-18 |
Bristol-Myers Squibb Co. |
Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
|
WO2003106438A1
(en)
|
2002-06-18 |
2003-12-24 |
The Scripps Research Institute |
Synthesis of diazonamide "a" core
|
US20040180855A1
(en)
|
2003-02-19 |
2004-09-16 |
Schumacher William A. |
Methods of treating thrombosis with reduced risk of increased bleeding times
|
US7138412B2
(en)
|
2003-03-11 |
2006-11-21 |
Bristol-Myers Squibb Company |
Tetrahydroquinoline derivatives useful as serine protease inhibitors
|
US7129264B2
(en)
|
2003-04-16 |
2006-10-31 |
Bristol-Myers Squibb Company |
Biarylmethyl indolines and indoles as antithromboembolic agents
|
WO2005014533A2
(en)
|
2003-08-08 |
2005-02-17 |
Transtech Pharma, Inc. |
Aryl and heteroaryl compounds, compositions, and methods of use
|
US7417063B2
(en)
|
2004-04-13 |
2008-08-26 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles useful as serine protease inhibitors
|
US7453002B2
(en)
|
2004-06-15 |
2008-11-18 |
Bristol-Myers Squibb Company |
Five-membered heterocycles useful as serine protease inhibitors
|
US7429604B2
(en)
|
2004-06-15 |
2008-09-30 |
Bristol Myers Squibb Company |
Six-membered heterocycles useful as serine protease inhibitors
|
BRPI0513310A
(pt)
|
2004-07-12 |
2008-05-06 |
Idun Pharmaceuticals Inc |
análogos de tetrapeptìdeo
|
EP1841504B1
(en)
|
2005-01-13 |
2014-11-19 |
Bristol-Myers Squibb Company |
Substituted biaryl compounds as factor xia inhibitors
|
WO2006089005A2
(en)
|
2005-02-17 |
2006-08-24 |
Bristol-Myers Squibb Company |
Combination of selective factor viia and/or xia and plasma kallikrein inhibitors
|
US20070111947A1
(en)
|
2005-10-14 |
2007-05-17 |
Mcmurry Thomas J |
Fibrin targeted therapeutics
|
WO2007054453A2
(en)
|
2005-11-11 |
2007-05-18 |
F. Hoffmann-La Roche Ag |
Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa
|
US8466295B2
(en)
|
2005-12-14 |
2013-06-18 |
Bristol-Myers Squibb Company |
Thiophene derivatives as factor XIa inhibitors
|
AU2006325746A1
(en)
|
2005-12-14 |
2007-06-21 |
Bristol-Myers Squibb Company |
Six-membered heterocycles useful as serine protease inhibitors
|
EP1981854B1
(en)
|
2005-12-14 |
2011-06-01 |
Bristol-Myers Squibb Company |
Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
|
PE20071132A1
(es)
|
2005-12-23 |
2007-12-14 |
Bristol Myers Squibb Co |
Compuestos macrociclicos como inhibidores del factor viia
|
EP2102189B1
(en)
|
2006-12-15 |
2015-07-29 |
Bristol-Myers Squibb Company |
Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
|
PE20081775A1
(es)
|
2006-12-20 |
2008-12-18 |
Bristol Myers Squibb Co |
Compuestos macrociclicos como inhibidores del factor viia
|
WO2008157162A1
(en)
|
2007-06-13 |
2008-12-24 |
Bristol-Myers Squibb Company |
Dipeptide analogs as coagulation factor inhibitors
|
ATE543811T1
(de)
|
2008-03-13 |
2012-02-15 |
Bristol Myers Squibb Co |
Pyridazinderivate als faktor-xia-inhibitoren
|
WO2010151317A1
(en)
|
2009-06-22 |
2010-12-29 |
Millennium Pharmaceuticals, Inc. |
Substituted hydroxamic acids and uses thereof
|
US8513433B2
(en)
|
2009-07-02 |
2013-08-20 |
Angion Biomedica Corp. |
Small molecule inhibitors of PARP activity
|
US8609676B2
(en)
|
2009-08-04 |
2013-12-17 |
Merck Sharp & Dohme, Corp. |
4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors
|
PE20160841A1
(es)
*
|
2010-02-11 |
2016-09-10 |
Bristol Myers Squibb Co |
Macrociclos como inhibidores del factor de coagulacion (fxia)
|
US9161924B2
(en)
|
2011-07-08 |
2015-10-20 |
Merck Sharp & Dohme Corp. |
Factor IXa inhibitors
|
TW201319068A
(zh)
*
|
2011-08-05 |
2013-05-16 |
必治妥美雅史谷比公司 |
作為xia因子抑制劑之環狀p1接合劑
|
TW201311689A
(zh)
|
2011-08-05 |
2013-03-16 |
必治妥美雅史谷比公司 |
作為因子xia抑制劑之新穎巨環化合物
|
US9108951B2
(en)
|
2011-10-14 |
2015-08-18 |
Bristol-Myers Squibb Company |
Substituted 5,6,7,8-tetrahydro-1,6-naphthyridines as factor XIa inhibitors
|
ES2579832T3
(es)
|
2011-10-14 |
2016-08-17 |
Bristol-Myers Squibb Company |
Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa
|
RS56168B1
(sr)
|
2011-10-14 |
2017-11-30 |
Bristol Myers Squibb Co |
Supstituisana jedinjenja tetrahidroizohinolina kao inhibitori xia faktora
|
GB2497806A
(en)
|
2011-12-21 |
2013-06-26 |
Ono Pharmaceutical Co |
Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
|
PL2794597T3
(pl)
|
2011-12-21 |
2018-03-30 |
Ono Pharmaceutical Co., Ltd. |
Pochodne pirydynonu i pirymidynonu jako inhibitory czynnika xia
|
WO2013111107A1
(en)
|
2012-01-27 |
2013-08-01 |
Novartis Ag |
Aminopyridine derivatives as plasma kallikrein inhibitors
|
WO2013111108A1
(en)
|
2012-01-27 |
2013-08-01 |
Novartis Ag |
5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
|
JP2015083542A
(ja)
|
2012-02-08 |
2015-04-30 |
大日本住友製薬株式会社 |
3位置換プロリン誘導体
|
US9783614B2
(en)
|
2012-05-10 |
2017-10-10 |
Bayer Pharma Aktiengesellschaft |
Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof
|
GB201209138D0
(en)
|
2012-05-24 |
2012-07-04 |
Ono Pharmaceutical Co |
Compounds
|
EP2876105A4
(en)
|
2012-07-19 |
2016-01-13 |
Sumitomo Dainippon Pharma Co Ltd |
1- (CYCLOALKYL-CARBONYL) PROLINE DERIVATIVE
|
CA2880898A1
(en)
*
|
2012-08-03 |
2014-02-06 |
Bristol-Myers Squibb Company |
Dihydropyridone p1 as factor xia inhibitors
|
US9409908B2
(en)
*
|
2012-08-03 |
2016-08-09 |
Bristol-Myers Squibb Company |
Dihydropyridone p1 as factor XIa inhibitors
|
EP2906541B1
(en)
|
2012-10-12 |
2017-11-22 |
Bristol-Myers Squibb Company |
Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
RS57039B1
(sr)
|
2012-10-12 |
2018-05-31 |
Bristol Myers Squibb Co |
Kristalni oblici inhibitora faktora xia
|
WO2014059202A1
(en)
|
2012-10-12 |
2014-04-17 |
Bristol-Myers Squibb Company |
Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
|
US9708308B2
(en)
|
2012-12-19 |
2017-07-18 |
Merck Sharp Dohme Corp. |
Factor IXa inhibitors
|
GB201300304D0
(en)
|
2013-01-08 |
2013-02-20 |
Kalvista Pharmaceuticals Ltd |
Benzylamine derivatives
|
GB2510407A
(en)
|
2013-02-04 |
2014-08-06 |
Kalvista Pharmaceuticals Ltd |
Aqueous suspensions of kallikrein inhibitors for parenteral administration
|
EP2978751B1
(en)
|
2013-03-25 |
2018-12-05 |
Bristol-Myers Squibb Company |
Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
|
TWI633089B
(zh)
|
2013-03-28 |
2018-08-21 |
拜耳製藥股份有限公司 |
經取代的酮基吡啶衍生物
|
CN105555767B
(zh)
|
2013-07-23 |
2018-03-23 |
拜耳制药股份公司 |
取代的氧代吡啶衍生物及其作为因子xia/血浆的用途
|
WO2015044172A1
(de)
|
2013-09-26 |
2015-04-02 |
Bayer Pharma Aktiengesellschaft |
Substituierte phenylalanin-derivate
|
EP3049404A1
(de)
|
2013-09-26 |
2016-08-03 |
Bayer Pharma Aktiengesellschaft |
Substituierte phenylalanin-derivate
|
WO2015044174A1
(de)
|
2013-09-26 |
2015-04-02 |
Bayer Pharma Aktiengesellschaft |
Substituierte phenylalanin-derivate als faktor xia modulatoren
|
CN105745192A
(zh)
|
2013-09-26 |
2016-07-06 |
拜耳制药股份公司 |
取代的苯丙氨酸衍生物
|
EP3049408A1
(de)
|
2013-09-26 |
2016-08-03 |
Bayer Pharma Aktiengesellschaft |
Substituierte phenylalanin-derivate
|
WO2015044173A1
(de)
|
2013-09-26 |
2015-04-02 |
Bayer Pharma Aktiengesellschaft |
Substituierte phenylalanin-derivate als faktor xia modulatoren
|
US20160244437A1
(en)
|
2013-09-26 |
2016-08-25 |
Bayer Pharma Aktiengesellschaft |
Substituted phenylalanine derivatives
|
WO2015044170A1
(de)
|
2013-09-26 |
2015-04-02 |
Bayer Pharma Aktiengesellschaft |
Substituierte phenylalanin-derivate und ihre verwendung zur behandlung von thrombotischen / thromboembolischen erkrankungen
|
US20160229839A1
(en)
|
2013-09-27 |
2016-08-11 |
Merck Sharp & Dohme Corp. |
Factor XIa Inhibitors
|
US20160257668A1
(en)
|
2013-10-07 |
2016-09-08 |
Merck Sharp & Dohme Corp. |
Factor XIa Inhibitors
|
JP6337750B2
(ja)
|
2013-11-22 |
2018-06-06 |
小野薬品工業株式会社 |
化合物
|
AU2014378428A1
(en)
|
2014-01-14 |
2016-09-01 |
Sumitomo Dainippon Pharma Co., Ltd. |
Condensed 5-oxazolidinone derivative
|
AU2015210904C1
(en)
|
2014-01-31 |
2019-08-29 |
Bristol-Myers Squibb Company |
Macrocycles with hetrocyclic P2' groups as factor XIa inhibitors
|
NO2760821T3
(bg)
|
2014-01-31 |
2018-03-10 |
|
|
CN108892661B
(zh)
|
2014-02-07 |
2023-03-14 |
艾克赛特赫拉制药有限责任公司 |
治疗化合物和组合物
|
EP3104701B1
(en)
|
2014-02-11 |
2019-01-30 |
Merck Sharp & Dohme Corp. |
Factor xia inhibitors
|
EP3104703B1
(en)
|
2014-02-11 |
2020-11-18 |
Merck Sharp & Dohme Corp. |
Factor xia inhibitors
|
EP3104702B1
(en)
|
2014-02-11 |
2022-08-10 |
Merck Sharp & Dohme LLC |
Factor xia inhibitors
|
EP3138839B1
(en)
|
2014-02-14 |
2020-10-28 |
Sichuan Haisco Pharmaceutical Co., Ltd. |
Pyridone or pyrimidone derivative, preparation method therefor and application thereof
|
BR112016020199A8
(pt)
|
2014-03-07 |
2021-07-20 |
Biocryst Pharm Inc |
composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
|
US9808445B2
(en)
|
2014-04-16 |
2017-11-07 |
Merck Sharp & Dohme Corp. |
Factor IXa inhibitors
|
WO2015160636A1
(en)
|
2014-04-16 |
2015-10-22 |
Merck Sharp & Dohme Corp. |
Factor ixa inhibitors
|
KR20150136294A
(ko)
|
2014-05-27 |
2015-12-07 |
주식회사 레고켐 바이오사이언스 |
인자 XIa 억제 활성을 가지는 신규한 화합물
|
MX2016015484A
(es)
|
2014-05-28 |
2017-03-23 |
Merck Sharp & Dohme |
Inhibidores del factor xia.
|
EP3197891B1
(de)
|
2014-09-24 |
2018-11-21 |
Bayer Pharma Aktiengesellschaft |
Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate
|
US9453018B2
(en)
|
2014-10-01 |
2016-09-27 |
Bristol-Myers Squibb Company |
Pyrimidinones as factor XIa inhibitors
|
NO2721243T3
(bg)
|
2014-10-01 |
2018-10-20 |
|
|
CA2970233C
(en)
|
2014-12-10 |
2023-01-03 |
Ono Pharmaceutical Co., Ltd. |
Dihydroindolizinone derivative
|
US10160750B2
(en)
|
2015-06-19 |
2018-12-25 |
Bristol-Myers Squibb Company |
Diamide macrocycles as factor XIa inhibitors
|